RXRX vs. RLAY

Last updated Aug 1, 2026

RXRX (Recursion Pharmaceuticals, Inc.) and RLAY (Relay Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, RXRX returned -37.05%/yr vs -10.31%/yr for RLAY. Their 0.49 correlation means their historical movements had little consistent relationship.

Performance

RXRX vs. RLAY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Relay Therapeutics, Inc. (RLAY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RXRX achieves a -26.65% return, which is significantly lower than RLAY's 122.58% return.

RXRX

• 1D: -1.32%
• 1M: -21.05%
• 6M: -28.40%
• YTD: -26.65%
• 1Y: -47.18%
• 3Y*: -39.89%
• 5Y*: -37.05%
• 10Y*: —
• ALL TIME*: -35.29%

RLAY

• 1D: -3.19%
• 1M: 0.97%
• 6M: 145.82%
• YTD: 122.58%
• 1Y: 460.42%
• 3Y*: 16.50%
• 5Y*: -10.31%
• 10Y*: —
• ALL TIME*: -9.75%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
RLAY Relay Therapeutics, Inc.	$42.00M	$52.39M	$63.55M
RXRX Recursion Pharmaceuticals, Inc.	$52.74M	$74.51M	$69.08M

RXRX vs. RLAY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RXRX Recursion Pharmaceuticals, Inc.	-26.65%	-39.50%	-31.44%	27.89%	-54.99%	-42.90%
RLAY Relay Therapeutics, Inc.	122.58%	105.34%	-62.58%	-26.31%	-51.35%	-8.95%

Correlation

The correlation between RXRX and RLAY is 0.35, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.35
Correlation (3Y) Balances recent behavior with more history.	0.47
Correlation (5Y) Shows whether the relationship held over a longer period.	0.50
Correlation (All Time) Calculated using the full available price history since Apr 16, 2021	0.49

The correlation between RXRX and RLAY shifts across timeframes, from 0.35 (1 year) to 0.50 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap RXRX : $1.57B RLAY : $3.30B
EPS RXRX : -$1.12 RLAY : -$1.56
PS Ratio RXRX : 22.67 RLAY : 307.94
PB Ratio RXRX : 1.55 RLAY : 5.27
Total Revenue (TTM) RXRX : $66.29M RLAY : $10.68M
Gross Profit (TTM) RXRX : -$22.83M RLAY : $6.33M
EBITDA (TTM) RXRX : -$505.90M RLAY : -$285.68M

Return for Risk

RXRX vs. RLAY — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

RXRX

RXRX Risk / Return Rank: 13
RXRX Sharpe Ratio Rank: 12
RXRX Sortino Ratio Rank: 13
RXRX Omega Ratio Rank: 16
RXRX Calmar Ratio Rank: 10
RXRX Martin Ratio Rank: 14

RLAY

RLAY Risk / Return Rank: 99
RLAY Sharpe Ratio Rank: 100
RLAY Sortino Ratio Rank: 99
RLAY Omega Ratio Rank: 97
RLAY Calmar Ratio Rank: 99
RLAY Martin Ratio Rank: 99

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

RXRX vs. RLAY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Relay Therapeutics, Inc. (RLAY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	RXRX	RLAY	Difference
Sharpe ratio: Return per unit of total volatility	-0.71	6.17	-6.88
Sortino ratio: Return per unit of downside risk	-0.96	5.06	-6.02
Omega ratio: Gain probability vs. loss probability	0.90	1.60	-0.70
Calmar ratio: Return relative to maximum drawdown	-0.85	15.58	-16.43
Martin ratio: Return relative to average drawdown	-1.25	44.72	-45.97

RXRX vs. RLAY - Sharpe Ratio Comparison

The current RXRX Sharpe Ratio is -0.71, which is lower than the RLAY Sharpe Ratio of 6.17. The chart below compares the historical Sharpe Ratios of RXRX and RLAY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

RXRX vs. RLAY - Drawdown Comparison

The maximum RXRX drawdown since its inception was -93.13%, roughly equal to the maximum RLAY drawdown of -96.75%. Use the drawdown chart below to compare losses from any high point for RXRX and RLAY.

Drawdown Indicators

	RXRX	RLAY	Difference
Max Drawdown Largest peak-to-trough decline	-93.13%	-96.75%	+3.62%
Max Drawdown (1Y) Largest decline over 1 year	-58.17%	-28.15%	-30.02%
Max Drawdown (3Y) Largest decline over 3 years	-81.70%	-83.43%	+1.73%
Max Drawdown (5Y) Largest decline over 5 years	-90.95%	-94.65%	+3.70%
Current Drawdown Current decline from peak	-92.74%	-69.40%	-23.34%
Average Drawdown Average peak-to-trough decline	-75.79%	-69.15%	-6.64%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.99%	9.79%	+30.20%

Volatility

RXRX vs. RLAY - Volatility Comparison

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 17.39% compared to Relay Therapeutics, Inc. (RLAY) at 15.29%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than RLAY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RXRX	RLAY	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.39%	15.29%	+2.10%
Volatility (6M) Calculated over the trailing 6-month period	45.40%	47.60%	-2.20%
Volatility (1Y) Calculated over the trailing 1-year period	69.61%	71.21%	-1.60%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.18%	78.64%	+14.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	92.91%	77.36%	+15.55%

Dividends

RXRX vs. RLAY - Dividend Comparison

Neither RXRX nor RLAY has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both RXRX and RLAY in my portfolio?

RXRX and RLAY have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RXRX or RLAY?

RXRX has higher volatility (17.39%) compared to RLAY (15.29%). In terms of maximum drawdown, RXRX dropped -93.13% vs RLAY's -96.75%.

Which has better risk-adjusted returns?

RLAY currently has the higher Sharpe Ratio (6.17 vs -0.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.